Driving Value Creation through Financing, Business Development, and M&A
New York
Chief Financial Officer
Aleksey Krylov is a seasoned Chief Financial
Officer (CFO) recognized for his experience in the life sciences and medical
technology sectors. With a background in venture investing and mergers and
acquisitions (M&A), his track record includes over 70 successful
fundraising and M&A transactions, which showcase his ability to navigate diverse
strategic opportunities for companies he works with.
As the CFO of CytoImmune Therapeutics, Aleksey
spearheaded a transformative period, securing over $100 million in funding and
overseeing the expansion of the workforce from five to over 60 employees.
Furthermore, he played a pivotal role in building a cutting-edge
commercial-scale cell and biologics manufacturing facility.
Previously, as CFO of DIH International,
Aleksey positioned the Swiss-Chinese medical equipment manufacturer for a targeted
NASDAQ public offering, driving strategic initiatives to optimize growth and maximize
shareholder value.
Aleksey's accomplishments extend to his role
as CFO of SELLAS Life Sciences, where he orchestrated a successful reverse
merger, which ultimately propelled the company to the market capitalization of several
hundred million dollars . He also led a successful convertible PIPE fundraise.
Before his stints as a healthcare CFO, Aleksey
spent 12 years as a family office investment professional. He oversaw principal
and control investments exceeding $500 million across diverse industries,
including life sciences, medical technologies, healthcare IT, and consumer
products. He started his career as an equity capital markets banker with
Cowen's healthcare practice.
Aleksey holds an MBA from Columbia Business
School and a Bachelor of Science in Business Administration from Babson
College. His ability to blend financial acumen, deal-making expertise, and
operational leadership makes him an invaluable asset to life sciences and
medical technology organizations, driving transformative growth and financial
performance.